BI 685509

Drug Profile

BI 685509

Latest Information Update: 19 Apr 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Kidney disorders

Most Recent Events

  • 06 Apr 2017 Boehringer Ingelheim plans a phase I trial for BI 685509 in Healthy volunteers in (Germany) (NCT03116893)
  • 06 Apr 2017 Boehringer Ingelheim plans a phase I trial for BI 685509 in Healthy volunteers in (Germany) (NCT03116906)
  • 25 Feb 2016 Preclinical trials in Undefined indication in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top